Status:
UNKNOWN
Sjogrens Syndrome Measured by Ultrasound
Lead Sponsor:
Arthritis & Rheumatism Associates, P.C.
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Sjogren's Syndrome
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Ultrasound study focused on salivary gland outcomes in Sjogren's subjects
Detailed Description
A 32 week ultrasound study for subject diagnosed with Sjogren's Syndrome. Subjects will receive Orencia (Abatacept) as intervention therapy during this trial.
Eligibility Criteria
Inclusion
- Subjects diagnosed with Sjogren's Syndrome
Exclusion
- Subjects previously diagnosed with Sarcoidsis
- Subjects with positive for Hepatitis B, Hepatitis C, HIV
- Subjects diagnosed with Cancer within 5 years of screening
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03411850
Start Date
May 1 2016
End Date
December 1 2021
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Center for Rheumatology and Bone Research a division of Arthritis and Rheumatism Associates, P.C.
Wheaton, Maryland, United States, 20902